UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 256

Sortiert nach

Breast cancer therapy in China: Introducing the Special Collection

Cancer, 2024-04, Vol.130 (S8), p.1368-1370

2024

Link zum Volltext

Verfügbarkeit prüfen

Triple-negative breast cancer in African-American women: disparities versus biology

Nature reviews. Cancer, 2015-04, Vol.15 (4), p.248

2015

Link zum Volltext

Verfügbarkeit prüfen

Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition

Journal of clinical oncology, 2022-04, Vol.40 (11), p.1142-1146

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeting forkhead box M1 transcription factor in breast cancer

Biochemical pharmacology, 2018-08, Vol.154, p.407-413

2018

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant cyclin‐dependent kinase 4/6 inhibition in hormone receptor–positive breast cancer: One Monarch to rule them all?

Cancer, 2021-09, Vol.127 (18), p.3302-3309

2021

Link zum Volltext

Verfügbarkeit prüfen

Therapy after cyclin‐dependent kinase inhibition in metastatic hormone receptor‐positive breast cancer: Resistance mechanisms and novel treatment strategies

Cancer, 2020-08, Vol.126 (15), p.3400-3416

2020

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

Breast cancer research and treatment, 2012-08, Vol.135 (1), p.39-48

2012

Link zum Volltext

Verfügbarkeit prüfen

When the personal becomes political: The impact of the Dobbs decision on women with cancer

Cancer, 2023-01, Vol.129 (2), p.171-174

2023

Link zum Volltext

Verfügbarkeit prüfen

Lymph node involvement: Positive about the role of the recurrence score in estrogen‐driven breast cancer?

Cancer, 2019-01, Vol.125 (2), p.177-180

2019

Link zum Volltext

Verfügbarkeit prüfen

Social media and clinical trials: The pros and cons gain context when the patient is at the center

Cancer, 2018-12, Vol.124 (24), p.4618-4621

2018

Link zum Volltext

Verfügbarkeit prüfen

Progress in breast cancer research amid the COVID‐19 gloom

Cancer, 2020-08, Vol.126 (S16), p.3809-3810

2020

Link zum Volltext

Verfügbarkeit prüfen

Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway

Clinical breast cancer, 2010-11, Vol.10, p.S72-S78

2010

Link zum Volltext

Verfügbarkeit prüfen

Emerging use of nanoparticles in diagnosis and treatment of breast cancer

The lancet oncology, 2006-08, Vol.7 (8), p.657-667

2006

Link zum Volltext

Verfügbarkeit prüfen

Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer

Cancer research (Chicago, Ill.), 2014-09, Vol.74 (18), p.5045-5056

2014

Link zum Volltext

Verfügbarkeit prüfen

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Clinical cancer research, 2021-06, Vol.27 (11), p.3061-3068

2021

Link zum Volltext

Verfügbarkeit prüfen

Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor

Cancer research (Chicago, Ill.), 2008-12, Vol.68 (23), p.9712-9722

2008

Link zum Volltext

Verfügbarkeit prüfen

Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer

Molecular cancer therapeutics, 2021-12, Vol.20 (12), p.2553-2567

2021

Link zum Volltext

Verfügbarkeit prüfen

The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer

Cancer research (Chicago, Ill.), 2019-03, Vol.79 (5), p.982-993

2019

Link zum Volltext

Verfügbarkeit prüfen

Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?

Clinical breast cancer, 2023-12, Vol.23 (8), p.813-824

2023

Link zum Volltext

Verfügbarkeit prüfen

Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells

Cancer research (Chicago, Ill.), 2008-04, Vol.68 (7), p.2479-2488

2008

Link zum Volltext

Verfügbarkeit prüfen

Systemic therapy for early‐stage HER2‐positive breast cancers: Time for a less‐is‐more approach?

Cancer, 2015-02, Vol.121 (4), p.517-526

2015

Link zum Volltext

Verfügbarkeit prüfen

Race, breast cancer, and prognosis: Where biology is queen?

Cancer, 2019-09, Vol.125 (18), p.3104-3106

2019

Link zum Volltext

Verfügbarkeit prüfen

PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer

International journal of molecular sciences, 2021-11, Vol.22 (21), p.11878

2021

Link zum Volltext

Verfügbarkeit prüfen

Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry

Nature protocols, 2007-05, Vol.2 (5), p.1152-1165

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 256

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(239)
Mit Volltextzugriff
(243)

Publikationsform

Sprache

Englisch
(256)
Japanisch
(26)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Breast cancer therapy in China: Introducing the Special Collection

Triple-negative breast cancer in African-American women: disparities versus biology

Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition

Targeting forkhead box M1 transcription factor in breast cancer

Adjuvant cyclin‐dependent kinase 4/6 inhibition in hormone receptor–positive breast cancer: One Monarch to rule them all?

Therapy after cyclin‐dependent kinase inhibition in metastatic hormone receptor‐positive breast cancer: Resistance mechanisms and novel treatment strategies

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

When the personal becomes political: The impact of the Dobbs decision on women with cancer

Lymph node involvement: Positive about the role of the recurrence score in estrogen‐driven breast cancer?

Social media and clinical trials: The pros and cons gain context when the patient is at the center

Progress in breast cancer research amid the COVID‐19 gloom

Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway

Emerging use of nanoparticles in diagnosis and treatment of breast cancer

Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor

Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer

Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?

Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells

Systemic therapy for early‐stage HER2‐positive breast cancers: Time for a less‐is‐more approach?

Race, breast cancer, and prognosis: Where biology is queen?

PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer

Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry

Suchergebnisse filtern